Human bone marrow mesenchymal stem cells for retinal vascular injury

Wang, Jinda; An, Ying; Zhang, Jingshang; Wan, Xiuhua; Jonas, Jost B; Xu, Liang; Zhang, Wei

doi:10.1111/aos.13154

Cited by 22 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravitreal administration of MSCs has demonstrated improvement in outcomes in several animal models of retinal injury and dysfunction (100–104); however, the safety of intravitreal injection of MSCs in humans is still an area of clinical concern (105).…”

Section: Routes Of Therapeutic Cell Deliverymentioning

confidence: 99%

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

et al. 2019

View full text Add to dashboard Cite

For several decades, multipotent mesenchymal stromal cells (MSCs) have been extensively studied for their therapeutic potential across a wide range of diseases. In the preclinical setting, MSCs demonstrate consistent ability to promote tissue healing, down-regulate excessive inflammation and improve outcomes in animal models. Several proposed mechanisms of action have been posited and demonstrated across an array of in vitro models. However, translation into clinical practice has proven considerably more difficult. A number of prominent well-funded late-phase clinical trials have failed, thus calling out for new efforts to optimize product delivery in the clinical setting. In this review, we discuss novel topics critical to the successful translation of MSCs from pre-clinical to clinical applications. In particular, we focus on the major routes of cell delivery, aspects related to hemocompatibility, and potential safety concerns associated with MSC therapy in the different settings.

show abstract

Section: Routes Of Therapeutic Cell Deliverymentioning

confidence: 99%

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Several studies have suggested that the successful reconstruction of damaged ocular tissues by MSCs was more dependent on the release of paracrine anti-inflammatory and anti-angiogenic factors than differentiation into ocular cells [120][121][122]. Thus, when human BMSCs were intravitreally implanted in an oxygen induced retinopathy mouse model, it significantly reduced retinal neovascularization [123]. When engineered to secrete therapeutic dose of anti-angiogenic factor PEDF, BMSCs were recruited to CNV lesions and inhibited neo-angiogenesis in vivo [124].…”

Section: Mscs Modulate Angiogenesismentioning

confidence: 99%

A Review on Mesenchymal Stem Cells for Treatment of Retinal Diseases

Adak

Magdalene

Deshmukh

et al. 2021

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Mesenchymal Stem Cells (MSCs) have been studied extensively for the treatment of several retinal diseases. The therapeutic potential of MSCs lies in its ability to differentiate into multiple lineages and secretome enriched with immunomodulatory, antiangiogenic and neurotrophic factors. Several studies have reported the role of MSCs in repair and regeneration of the damaged retina where the secreted factors from MSCs prevent retinal degeneration, improve retinal morphology and function. MSCs also donate mitochondria to rescue the function of retinal cells and exosomes secreted by MSCs were found to have anti-apoptotic and anti-inflammatory effects. Based on several promising results obtained from the preclinical studies, several clinical trials were initiated to explore the potential advantages of MSCs for the treatment of retinal diseases. This review summarizes the various properties of MSCs that help to repair and restore the damaged retinal cells and its potential for the treatment of retinal degenerative diseases. Key words Retinal regeneration . cell replacement therapy . exosomes . mitochondrial transfer . anti-inflammatory molecules Abbreviations AMD Age-related macular degeneration ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 ACE2 Angiotensin converting enzyme 2 ADSCs Adipose tissue derived mesenchymal stem cells AMSCs Amniotic membrane derived mesenchymal stem cells APCs Antigen presenting cells ASCs Adipose tissue derived stromal cells BCL-XL B-cell lymphoma-extra-large-protein BCVA Best corrected visual acuity BDNF Brain derived neurotrophic factor BM Bruch's membrane

show abstract

“…In this study, we found that the BMSC remodeled the vascular network and reduced the avascular areas and neovascularization. Similar effects were observed in multiple animal models of retinal neovascularization by using human BMSC [11]. However, we specifically examined the role of BMSC and compared with Conbercept, which is an important anti-VEGF drug that is clinically used for the treatment of ocular neovascularization.…”

Section: Retinal Histology and Apoptosis Assaymentioning

confidence: 71%

Therapeutic effect against retinal neovascularization in a mouse model of oxygen-induced retinopathy: bone marrow-derived mesenchymal stem cells versus Conbercept

Cheng

Cui

et al. 2020

BMC Ophthalmol

View full text Add to dashboard Cite

Background: To study the therapeutic effect of bone marrow-derived mesenchymal stem cells (BMSC) against retinal neovascularization and to compare with anti-vascular endothelial growth factor (VEGF) therapy. Methods: Neonatal C57BL/6 mice were exposed in hyperoxygen and returned to room air to develop oxygeninduced retinopathy (OIR). Red fluorescent protein-labeled BMSC and Conbercept were intravitreally injected into OIR mice, respectively. Inhibition of neovascularization and apoptosis in OIR mice were assessed through retinal angiography, histopathology and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. Results: BMSC were able to migrate and integrate into the host retina, significantly inhibit retinal neovascular tufts and remodel the capillary network after injecton. Treatment with BMSC increased the retinal vascular density, decreased the number of acellular capillaries and inhibited retinal cell death. This effect was not inferior to current anti-VEGF therapy by using Conbercept. Conclusions: Intravitreal injection of BMSC exerts a protective effect against retinal neovascularization and offers a therapeutic strategy for oxygen-induced retinopathy.

show abstract

Human bone marrow mesenchymal stem cells for retinal vascular injury

Cited by 22 publications

References 34 publications

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

A Review on Mesenchymal Stem Cells for Treatment of Retinal Diseases

Therapeutic effect against retinal neovascularization in a mouse model of oxygen-induced retinopathy: bone marrow-derived mesenchymal stem cells versus Conbercept

Contact Info

Product

Resources

About